SG&A Spending Patterns: Alkermes plc vs. Rhythm Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Over the past decade, Alkermes plc and Rhythm Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc's SG&A expenses surged by approximately 245%, reflecting a robust growth strategy. In contrast, Rhythm Pharmaceuticals, Inc. experienced a staggering increase of over 9,600% in the same period, indicating aggressive expansion efforts.

Alkermes plc maintained a steady increase, with expenses peaking in 2023, while Rhythm Pharmaceuticals, Inc. showed a more volatile pattern, with significant jumps post-2018. This divergence highlights different strategic approaches: Alkermes focusing on steady growth and Rhythm on rapid scaling. These insights provide a window into the companies' operational priorities and market positioning strategies.